Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03349775 · ClinicalTrials.gov registry record · Early Phase 1
Cardiometabolic Disease and Pulmonary Hypertension
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT03349775: Clinical Trial Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT03349775 is a Early Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03349775, a Early Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study will investigate if metformin can help people with obesity and high pressures inside their lung blood vessels. Metformin is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, but metformin is not approved by the FDA to treat pulmonary hypertension. This study will examine whether Metformin will improve the high pressure inside lung blood vessels in people who are obese. The study will help understand the effect of metformin on pressures inside lung blood vessels.
Interventions
- DRUG Placebo
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2020-12-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03349775
The ClinicalTrials.gov registry entry for NCT03349775 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03349775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03349775 about?
NCT03349775 is a clinical study titled "Cardiometabolic Disease and Pulmonary Hypertension". This study will investigate if metformin can help people with obesity and high pressures inside their lung blood vessels. Metformin is approved by the U.S. Food and Drug Administration (FDA) to treat diabetes, but metformin is not approved by the FDA to treat pulmonary hypertension. This study will...
What is the current status of trial NCT03349775?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2017-11-27. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT03349775?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).
Who is sponsoring clinical trial NCT03349775?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.